4 results on '"Omlor AJ"'
Search Results
2. Preclinical Evaluation of a New ECCO2R Setup.
- Author
-
Schwärzel LS, Jungmann AM, Schmoll N, Caspari S, Seiler F, Muellenbach RM, Bewarder M, Thai Dinh Q, Bals R, Lepper PM, and Omlor AJ
- Subjects
- Adult, Carbon Dioxide, Child, Extracorporeal Circulation, Humans, Hypercapnia, Respiration, Artificial, Respiratory Distress Syndrome therapy, Respiratory Insufficiency
- Abstract
Low flow extracorporeal carbon dioxide removal (ECCO2R) is a promising approach to correct hypercapnic lung failure, facilitate lung protective ventilation in acute respiratory distress syndrome and to possibly prevent the application of invasive ventilation. However, the predominant availability of adult membrane lungs (MLs) at most intensive care units are burdens for low flow ECCO2R that intends to reduce cannula size and promote the mobility of the patients. Herein, in a mock setup, we combine the idea of a low flow ECCO2R and the use of adult MLs by installing a recirculation channel into the circuit and comparing the new setup to an already clinically established setup, "the Homburg lung." Furthermore, to make stronger reference to hypercapnic respiratory failure, we investigate the influence of CO2 partial pressure in blood on CO2 removal of both setups. A linear association between CO2 partial pressure in blood and CO2 removal of the ML in the physiologically relevant range was observed. To understand this linear dependence, a simplified mathematical model was proposed. Our new ECCO2R mock setup combines the idea of a low flow ECCO2R and an adult size ML. It shows a reasonable alternative to the current available low flow setups based on pediatric MLs., Competing Interests: Disclosure: The authors have no funding and conflicts of interest to report., (Copyright © ASAIO 2022.)
- Published
- 2022
- Full Text
- View/download PDF
3. Injection of Recombinant Tissue Plasminogen Activator into Extracorporeal Membrane Oxygenators Postpones Oxygenator Exchange in COVID-19.
- Author
-
Mang S, Danziger G, Metz C, Rixecker T, Becker A, Omlor AJ, Jentgen C, Schmoll C, Seiler F, Reyher C, Muellenbach RM, Bals R, and Lepper PM
- Subjects
- Blood Gas Analysis, Humans, Extracorporeal Membrane Oxygenation instrumentation, Extracorporeal Membrane Oxygenation methods, Oxygenators, Membrane, Tissue Plasminogen Activator therapeutic use, COVID-19 Drug Treatment
- Abstract
Coronavirus disease 2019 (COVID-19) has drastically increased the number of patients requiring extracorporeal life support. We investigate the efficacy and safety of low-dose recombinant tissue-type plasminogen activator (rtPA) injection into exhausted oxygenators to delay exchange in critically ill COVID-19 patients on veno-venous extracorporeal membrane oxygenation (V-V ECMO). Small doses of rtPA were injected directly into the draining section of a V-V ECMO circuit. We compared transmembrane pressure gradient, pump head efficiency, membrane arterial partial oxygen pressure, and membrane arterial partial carbon dioxide pressure before and after the procedure. Bleeding was compared with a matched control group of 20 COVID-19 patients on V-V ECMO receiving standard anticoagulation. Four patients received 16 oxygenator instillations with rtPA at 5, 10, or 20 mg per dose. Administration of rtPA significantly reduced transmembrane pressure gradient (Δ pm = 54.8 ± 18.1 mmHg before vs . 38.3 ± 13.3 mmHg after, p < 0.001) in a dose-dependent manner (Pearson's R -0.63, p = 0.023), allowing to delay oxygenator exchange, thus reducing the overall number of consumed oxygenators. rtPA increased blood flow efficiency η (1.20 ± 0.28 ml/revolution before vs . 1.24 ± 0.27 ml/r, p = 0.002). Lysis did not affect membrane blood gases or systemic coagulation. Minor bleeding occurred in 2 of 4 patients (50%) receiving oxygenator lysis as well as 19 of 20 control patients (95%). Lysis of ECMO oxygenators effectively delays oxygenator exchange, if exchange is indicated by an increase in transmembrane pressure gradient. Application of lysis did not result in higher bleeding incidences compared with anticoagulated patients on V-V ECMO for COVID-19., Competing Interests: Robert Bals declares funding from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Grifols, Novartis, CLS Behring, the German Federal Ministry of Education and Research (BMBF) Competence Network Asthma and COPD (ASCONET), Sander-Stiftung, Schwiete-Stiftung, Krebshilfe and Mukoviszidose eV. FS received travel reimbursement from Getinge. Conflicts that the editors consider relevant to the content of the article have been disclosed. All other authors declare no potential conflicts of interest., (Copyright © ASAIO 2022.)
- Published
- 2022
- Full Text
- View/download PDF
4. First Use of a New Extracorporeal Membrane Oxygenation System in COVID19-Associated Adult Respiratory Distress Syndrome: The MobyBox Device.
- Author
-
Kau M, Steltner JC, Lepper PM, Omlor AJ, Mang S, Misic J, Peivandi AA, Muellenbach RM, and Reyher C
- Subjects
- Adult, Humans, Retrospective Studies, COVID-19, Extracorporeal Membrane Oxygenation adverse effects, Respiratory Distress Syndrome etiology, Respiratory Distress Syndrome therapy
- Abstract
In late 2020, during the second wave of COVID-19 in Germany, we started using the MobyBox, which is a novel fully pneumatically driven ECMO device, on a regular basis to meet the increasing demand for ECMO therapy. In this case series, we performed a retrospective chart review of seven patients with severe COVID-19-related acute respiratory distress syndrome (ARDS) requiring veno-venous (vv)-ECMO support with the MobyBox. During ECMO treatments we have observed no disadvantages in comparison to conventional ECMO systems. There were no system failures or adverse events directly attributable to the MobyBox system. Our data support that providing vv-ECMO with the MobyBox device is safe and feasible. Furthermore, our findings suggest that the MobyBox device might represent an advantage in terms of biocompatibility. Therefore, more data on this issue is needed to better understand how the pneumatically driven pump affects cellular blood components., Competing Interests: Disclosure: R.M.M. has been in the medical advisory board of Hemovent. The remaining authors have no conflicts of interest to disclose., (Copyright © ASAIO 2022.)
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.